Corcept Therapeutics (CORT) EBITDA Margin (2012 - 2026)
Corcept Therapeutics (CORT) posted EBITDA Margin of 16.12% for Q2 2026, up 153.6% sequentially from 30.08% in Q1 2026, and up 240.0% YoY from 4.74% in Q2 2025.
Corcept Therapeutics (CORT) EBITDA Margin (2012 - 2026) Analysis & Trends
Corcept Therapeutics has reported EBITDA Margin for 15 years, with the latest figure at 16.12% in Q2 2026.
- Quarterly EBITDA Margin rose 240.0% year-over-year to 16.12% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.77% (down 1347.0% YoY) and the FY2025 annual result came in at 5.88%, down 1440.0% from the prior year.
- EBITDA Margin improved to 16.12% in Q2 2026 per CORT's latest filing, from 30.08% in the prior quarter.
- Over five years, EBITDA Margin peaked at 31.39% in Q3 2022 and troughed at 30.08% in Q1 2026.
- A 5-year average of 16.13% and a median of 20.91% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2026: EBITDA Margin surged 604 bps in 2024, then sank 3225 bps in 2026.
- Over 5 years, EBITDA Margin stood at 21.83% in 2022, then increased by 7 bps to 23.39% in 2023, then plunged by 41 bps to 13.89% in 2024, then sank by 84 bps to 2.22% in 2025, then soared by 626 bps to 16.12% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 16.12%, 30.08%, and 2.22% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 16.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.12% |
| Mar 31, 2026 | -30.08% |
| Dec 31, 2025 | 2.22% |
| Sep 30, 2025 | 4.92% |
| Jun 30, 2025 | 13.72% |
| Mar 31, 2025 | 2.17% |
| Dec 31, 2024 | 13.89% |
| Sep 30, 2024 | 25.53% |
| Jun 30, 2024 | 21.73% |
| Mar 31, 2024 | 20.09% |
| Dec 31, 2023 | 23.39% |
| Sep 30, 2023 | 25.22% |
| Jun 30, 2023 | 25.13% |
| Mar 31, 2023 | 14.06% |
| Dec 31, 2022 | 21.83% |
| Sep 30, 2022 | 31.39% |
| Jun 30, 2022 | 30.40% |
| Mar 31, 2022 | 28.57% |
| Dec 31, 2021 | 37.10% |
| Sep 30, 2021 | 37.69% |